A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.

ABSTRACT:

Background

Optimization of risk stratification is important for facilitating prognoses and therapeutic decisions regarding diffuse large B-cell lymphoma (DLBCL). However, a simple and applicable prognostic tool is lacking for individuals with human immunodeficiency virus (HIV)-related DLBCL in the era of combined antiretroviral therapy (cART).

Methods

This retrospective multicenter observational study included 147 HIV-related DLBCL patients with histologically confirmed DLBCL from 2013 to 2020. The total group was divided into training (n = 78) and validation (n = 69) cohorts to derive the best prognostic score. Clinicopathological and characteristic biomarkers correlated with clinical outcomes were analyzed.

Results

Age, Ann Arbor stage, lactate dehydrogenase (LDH) r

SUBMITTER: Chen J 

PROVIDER: S-EPMC10278482 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature